The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder

被引:21
|
作者
Friesen, Erik Loewen [1 ,2 ,3 ]
Kurdyak, Paul [1 ,3 ,4 ]
机构
[1] Univ Toronto, Inst Hlth Policy Management & Evaluat, 155 Coll St 4th Floor, Toronto, ON M5T 3M6, Canada
[2] Univ Toronto, Fac Med, Toronto, ON, Canada
[3] Ctr Addict & Mental Hlth, Toronto, ON, Canada
[4] ICES, Toronto, ON, Canada
关键词
Opioid use disorder; Psychiatry; Mental health; Medication for opioid use disorder; Treatment discontinuation; SUBSTANCE USE; TREATMENT COMPLETION; BUPRENORPHINE/NALOXONE TREATMENT; METHADONE; PREDICTORS; DEPENDENCE; DISPARITIES; ATTRITION; EPIDEMIC; DROPOUT;
D O I
10.1016/j.drugalcdep.2020.108244
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Psychiatric illness complicates the clinical course of opioid use disorder (OUD) including treatment using medication for OUD (MOUD). The purpose of this study was to assess the relationship between psychiatric comorbidity and MOUD discontinuation, stratified by whether the client dropped out of treatment or whether MOUD was terminated by the addiction facility. Methods: The study population consisted of individuals with OUD receiving MOUD. Data was derived from the 2015-2017 Treatment Episodes Dataset - Discharges (TEDS-D), which includes discharge records from addiction treatment centers across the United States. The association between psychiatric comorbidity and MOUD discontinuation (including client dropout and facility termination) was assessed using multivariable logistic regression models that included clinically relevant covariates (age, sex, race, education, employment status, living arrangement, prior addiction treatment, intravenous opioid use, primary opioid used at admission, polysubstance use, previous arrests, length of stay, and referral source). Results: Psychiatric comorbidity decreased the odds of client dropout (adjusted odds ratio (aOR): 0.88, 95 % confidence interval (CI): 0.86 - 0.89) but increased the odds of MOUD being terminated by the treatment facility (aOR: 1.59, 95 % CI: 1.56-1.63). The association between psychiatric comorbidity and MOUD discontinuation varied considerably between states. Conclusions: Individuals with psychiatric illness are slightly less likely to drop out of MOUD treatment but are more likely to have their treatment prematurely terminated by the treatment facility. This emphasizes the importance of considering psychiatric illness when providing OUD treatment and suggests that measures to improve MOUD retention for individuals with psychiatric illness are required.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder
    Gopaldas, Manesh
    Wenzel, Kevin
    Campbell, Aimee N. C.
    Jalali, Ali
    Fishman, Marc
    Rotrosen, John
    V. Nunes, Edward
    Murphy, Sean M.
    PSYCHIATRIC SERVICES, 2023, 74 (12) : 1227 - 1233
  • [32] Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings
    Pham, Huyen
    Ober, Allison
    Baldwin, Laura-Mae
    Mooney, Larissa J.
    Zhu, Yuhui
    Fei, Zhe
    Hser, Yih-Ing
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (03) : 331 - 334
  • [33] Substance use disorder comorbidity among inpatient youths with psychiatric disorder
    Swadi, H
    Bobier, C
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2003, 37 (03): : 294 - 298
  • [34] Intra-individual variability and stability of affect and craving among individuals receiving medication treatment for opioid use disorder
    Jennifer D. Ellis
    Chung Jung Mun
    David H. Epstein
    Karran A. Phillips
    Patrick H. Finan
    Kenzie L. Preston
    Neuropsychopharmacology, 2022, 47 : 1836 - 1843
  • [35] Intra-individual variability and stability of affect and craving among individuals receiving medication treatment for opioid use disorder
    Ellis, Jennifer D.
    Mun, Chung Jung
    Epstein, David H.
    Phillips, Karran A.
    Finan, Patrick H.
    Preston, Kenzie L.
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (10) : 1836 - 1843
  • [36] Recovery capital among people receiving treatment for opioid use disorder with buprenorphine
    Anna Beth Parlier-Ahmad
    Mishka Terplan
    Dace S. Svikis
    Laura Ellis
    Caitlin E. Martin
    Harm Reduction Journal, 18
  • [37] Recovery capital among people receiving treatment for opioid use disorder with buprenorphine
    Parlier-Ahmad, Anna Beth
    Terplan, Mishka
    Svikis, Dace S.
    Ellis, Laura
    Martin, Caitlin E.
    HARM REDUCTION JOURNAL, 2021, 18 (01)
  • [38] The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review
    Cayley Russell
    Justine Law
    Sameer Imtiaz
    Jürgen Rehm
    Bernard Le Foll
    Farihah Ali
    Addiction Science & Clinical Practice, 18
  • [39] Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder
    Anna Beth Parlier-Ahmad
    Mickeal Pugh
    Caitlin E. Martin
    Journal of Racial and Ethnic Health Disparities, 2022, 9 : 1557 - 1567
  • [40] The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review
    Russell, Cayley
    Law, Justine
    Imtiaz, Sameer
    Rehm, Juergen
    Le Foll, Bernard
    Ali, Farihah
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)